{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:20Z","timestamp":1788274340360,"version":"build-2803163510"},"reference-count":131,"publisher":"Zhejiang University Press","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"DOI":"10.1631\/jzus.b2400146","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:15:04Z","timestamp":1765433704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies","PARP \u6291\u5236\u5242\u5728\u764c\u75c7\u6cbb\u7597\u4e2d\u7684\u672a\u6765: \u901a\u8fc7\u8054\u5408\u7597\u6cd5\u514b\u670d\u8010\u836f\u6027\u5e76\u63d0\u9ad8\u7597\u6548"],"prefix":"10.1631","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-1840","authenticated-orcid":false,"given":"Muhammad","family":"Shoaib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-425X","authenticated-orcid":false,"given":"Zeeshan Ahmad","family":"Bhutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1925-1198","authenticated-orcid":false,"given":"Kyung-Chul","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-5855","authenticated-orcid":false,"given":"Wanxia","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"S5","key":"816_CR1","doi-asserted-by":"publisher","first-page":"v327","DOI":"10.1093\/annonc\/mdz248.003","volume":"30","author":"W Abida","year":"2019","unstructured":"Abida W, Campbell D, Patnaik A, et al., 2019. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (MCRPC): updated analyses. Ann Oncol, 30(S5):v327\u2013v328. https:\/\/doi.org\/10.1093\/annonc\/mdz248.003","journal-title":"Ann Oncol"},{"key":"816_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","volume":"9","author":"GP Amarante-Mendes","year":"2018","unstructured":"Amarante-Mendes GP, Adjemian S, Branco LM, et al., 2018. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol, 9:2379. https:\/\/doi.org\/10.3389\/fimmu.2018.02379","journal-title":"Front Immunol"},{"key":"816_CR3","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","volume":"10","author":"AA Antolin","year":"2020","unstructured":"Antolin AA, Ameratunga M, Banerji U, et al., 2020. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep, 10:2585. https:\/\/doi.org\/10.1038\/s41598-020-59074-4","journal-title":"Sci Rep"},{"key":"816_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, et al., 2019. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol, 11:543\u2013561. https:\/\/doi.org\/10.2147\/CLEP.S206949","journal-title":"Clin Epidemiol"},{"issue":"5\u20136","key":"816_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1101\/gad.334730.119","volume":"34","author":"K Azarm","year":"2020","unstructured":"Azarm K, Smith S, 2020. Nuclear PARPs and genome integrity. Genes Dev, 34(5\u20136):285\u2013301. https:\/\/doi.org\/10.1101\/gad.334730.119","journal-title":"Genes Dev"},{"issue":"7","key":"816_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","volume":"28","author":"MR Baer","year":"2022","unstructured":"Baer MR, Kogan AA, Bentzen SM, et al., 2022. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia. Clin Cancer Res, 28(7):1313\u20131322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3729","journal-title":"Clin Cancer Res"},{"issue":"9","key":"816_CR7","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1093\/nar\/gku174","volume":"42","author":"C Beck","year":"2014","unstructured":"Beck C, Boehler C, Guirouilh Barbat J, et al., 2014. PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Res, 42(9):5616\u20135632. https:\/\/doi.org\/10.1093\/nar\/gku174","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"816_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41580-020-0257-5","volume":"21","author":"M Berti","year":"2020","unstructured":"Berti M, Cortez D, Lopes M, 2020. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress. Nat Rev Mol Cell Biol, 21(10):633\u2013651. https:\/\/doi.org\/10.1038\/s41580-020-0257-5","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"816_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s43188-024-00246-z","volume":"10","author":"ZA Bhutta","year":"2024","unstructured":"Bhutta ZA, Go RE, Choi KC, 2024. Effect of punicalagin on the autophagic cell death in triple-negative breast cancer cells. Toxicol Res, 10(4):585\u2013598. https:\/\/doi.org\/10.1007\/s43188-024-00246-z","journal-title":"Toxicol Res"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-019-08530-5","volume":"10","author":"CJ Bian","year":"2019","unstructured":"Bian CJ, Zhang C, Luo T, et al., 2019. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun, 10:693. https:\/\/doi.org\/10.1038\/s41467-019-08530-5","journal-title":"Nat Commun"},{"key":"816_CR11","doi-asserted-by":"publisher","unstructured":"Boumehira AZ, Akchiche YF, Cherfi W, et al., 2022. Metabolomics approaches for early cancer diagnosis: a review. Asian J Agric Biol, (4):202012566. https:\/\/doi.org\/10.35495\/ajab.2020.12.566","DOI":"10.35495\/ajab.2020.12.566"},{"issue":"1","key":"816_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10637-019-00867-4","volume":"38","author":"S Boussios","year":"2020","unstructured":"Boussios S, Karihtala P, Moschetta M, et al., 2020. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs, 38(1): 181\u2013193. https:\/\/doi.org\/10.1007\/s10637-019-00867-4","journal-title":"Invest New Drugs"},{"issue":"1","key":"816_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2019.09.024","volume":"77","author":"E Callen","year":"2020","unstructured":"Callen E, Zong DL, Wu W, et al., 2020. 53BP1 enforces distinct pre- and post-resection blocks on homologous recombination. Mol Cell, 77(1):26\u201338.e7. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.024","journal-title":"Mol Cell"},{"issue":"10","key":"816_CR14","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/ijc.33038","volume":"147","author":"D Caracciolo","year":"2020","unstructured":"Caracciolo D, Riillo C, Arbitrio M, et al., 2020. Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. Int J Cancer, 147(10):2658\u20132668. https:\/\/doi.org\/10.1002\/ijc.33038","journal-title":"Int J Cancer"},{"issue":"6","key":"816_CR15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cancers13061392","volume":"13","author":"D Caracciolo","year":"2021","unstructured":"Caracciolo D, Riillo C, di Martino MT, et al., 2021. Alternative non-homologous end-joining: error-prone DNA repair as cancer\u2019s Achilles\u2019 heel. Cancers (Basel), 13(6): 1392. https:\/\/doi.org\/10.3390\/cancers13061392","journal-title":"Cancers (Basel)"},{"issue":"1","key":"816_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0006-291X(63)90024-X","volume":"11","author":"P Chambon","year":"1963","unstructured":"Chambon P, Weill JD, Mandel P, 1963. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun, 11(1):39\u201343. https:\/\/doi.org\/10.1016\/0006-291X(63)90024-X","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"816_CR17","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.3390\/cancers13184520","volume":"13","author":"WY Chan","year":"2021","unstructured":"Chan WY, Brown LJ, Reid L, et al., 2021. PARP inhibitors in melanoma\u2014an expanding therapeutic option? Cancers (Basel), 13(18):4520. https:\/\/doi.org\/10.3390\/cancers13184520","journal-title":"Cancers (Basel)"},{"key":"816_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biochi.2021.07.006","volume":"190","author":"S Chaudhari","year":"2021","unstructured":"Chaudhari S, Ware AP, Jayaram P, et al., 2021. Apurinic\/ Apyrimidinic Endonuclease 2 (APE2): an ancillary enzyme for contextual base excision repair mechanisms to preserve genome stability. Biochimie, 190:70\u201390. https:\/\/doi.org\/10.1016\/j.biochi.2021.07.006","journal-title":"Biochimie"},{"issue":"3","key":"816_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","volume":"14","author":"YE Choi","year":"2016","unstructured":"Choi YE, Meghani K, Brault ME, et al., 2016. Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep, 14(3): 429\u2013439. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.046","journal-title":"Cell Rep"},{"key":"816_CR20","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/s41467-020-19961-w","volume":"11","author":"KE Clements","year":"2020","unstructured":"Clements KE, Schleicher EM, Thakar T, et al., 2020. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun, 11:6118. https:\/\/doi.org\/10.1038\/s41467-020-19961-w","journal-title":"Nat Commun"},{"issue":"10106","key":"816_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al., 2017. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10106):1949\u20131961. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6","journal-title":"Lancet"},{"issue":"15","key":"816_CR22","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong K, Peng M, Kousholt AN, et al., 2021. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell, 81(15):3128\u20133144.e7. https:\/\/doi.org\/10.1016\/j.molcel.2021.06.011","journal-title":"Mol Cell"},{"key":"816_CR23","series-title":"PhD Thesis","doi-asserted-by":"publisher","DOI":"10.17863\/CAM.52723","volume-title":"Mechanisms of human RAD51 regulation by RAD52 and BRCA2","author":"S Constantinou","year":"2019","unstructured":"Constantinou S, 2019. Mechanisms of human RAD51 regulation by RAD52 and BRCA2. PhD Thesis, University of Cambridge, UK. https:\/\/doi.org\/10.17863\/CAM.52723"},{"issue":"10","key":"816_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C, 2020. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov, 19(10):711\u2013736. https:\/\/doi.org\/10.1038\/s41573-020-0076-6","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"816_CR25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al., 2020. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med, 382(22):2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"issue":"8","key":"816_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.tcb.2021.04.002","volume":"31","author":"I de Krijger","year":"2021","unstructured":"de Krijger I, Boersma V, Jacobs JJL, 2021. REV7: jack of many trades. Trends Cell Biol, 31(8):686\u2013701. https:\/\/doi.org\/10.1016\/j.tcb.2021.04.002","journal-title":"Trends Cell Biol"},{"issue":"12","key":"816_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, et al., 2021. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol, 18(12):773\u2013791. https:\/\/doi.org\/10.1038\/s41571-021-00532-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"S4","key":"816_CR28","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.annonc.2020.08.953","volume":"31","author":"Y Drew","year":"2020","unstructured":"Drew Y, Penson RT, O\u2019Malley DM, et al., 2020. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with nongermline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol, 31(S4): S615\u2013S616. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.953","journal-title":"Ann Oncol"},{"issue":"9","key":"816_CR29","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","volume":"29","author":"J Ettl","year":"2018","unstructured":"Ettl J, Quek RGW, Lee KH, et al., 2018. Quality of life with talazoparib versus physician\u2019s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol, 29(9):1939\u20131947. https:\/\/doi.org\/10.1093\/annonc\/mdy257","journal-title":"Ann Oncol"},{"issue":"10","key":"816_CR30","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, et al., 2019. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov, 9(10):1372\u20131387. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0582","journal-title":"Cancer Discov"},{"issue":"12","key":"816_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers10120487","volume":"10","author":"I Faraoni","year":"2018","unstructured":"Faraoni I, Graziani G, 2018. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel), 10(12):487. https:\/\/doi.org\/10.3390\/cancers10120487","journal-title":"Cancers (Basel)"},{"key":"816_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bcp.2019.04.019","volume":"167","author":"I Faraoni","year":"2019","unstructured":"Faraoni I, Giansanti M, Voso MT, et al., 2019. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochem Pharmacol, 167:133\u2013148. https:\/\/doi.org\/10.1016\/j.bcp.2019.04.019","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"816_CR33","doi-asserted-by":"publisher","first-page":"e1000855","DOI":"10.1371\/journal.pgen.1000855","volume":"6","author":"F Fattah","year":"2010","unstructured":"Fattah F, Lee EH, Weisensel N, et al., 2010. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genetics, 6(2):e1000855. https:\/\/doi.org\/10.1371\/journal.pgen.1000855","journal-title":"PLoS Genetics"},{"issue":"9","key":"816_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C, et al., 2018. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer, 119(9): 1075\u20131085. https:\/\/doi.org\/10.1038\/s41416-018-0271-y","journal-title":"Br J Cancer"},{"issue":"S9","key":"816_CR35","doi-asserted-by":"publisher","first-page":"ix89","DOI":"10.1093\/annonc\/mdz426.039","volume":"30","author":"K Fujiwara","year":"2019","unstructured":"Fujiwara K, Vergote IB, Sehouli J, et al., 2019. ENGOT-ov43\/KEYLYNK-001: a phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. Ann Oncol, 30(S9):ix89. https:\/\/doi.org\/10.1093\/annonc\/mdz426.039","journal-title":"Ann Oncol"},{"issue":"6","key":"816_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, et al., 2021. Epidemiology and prevention of prostate cancer. Eur Urol Oncol, 4(6):877\u2013892. https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"816_CR37","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","volume":"98","author":"TJ Gaymes","year":"2013","unstructured":"Gaymes TJ, Mohamedali AM, Patterson M, et al., 2013. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica, 98(9):1397\u20131406. https:\/\/doi.org\/10.3324\/haematol.2012.079251","journal-title":"Haematologica"},{"issue":"5","key":"816_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","volume":"14","author":"A George","year":"2017","unstructured":"George A, Kaye S, Banerjee S, 2017. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol, 14(5):284\u2013296. https:\/\/doi.org\/10.1038\/nrclinonc.2016.191","journal-title":"Nat Rev Clin Oncol"},{"key":"816_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fphar.2019.00385","volume":"10","author":"AK Giri","year":"2019","unstructured":"Giri AK, Aittokallio T, 2019. DNMT inhibitors increase methylation in the cancer genome. Front Pharmacol, 10:385. https:\/\/doi.org\/10.3389\/fphar.2019.00385","journal-title":"Front Pharmacol"},{"issue":"6","key":"816_CR40","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cancers14061420","volume":"14","author":"E Giudice","year":"2022","unstructured":"Giudice E, Gentile M, Salutari V, et al., 2022. PARP inhibitors resistance: mechanisms and perspectives. Cancers (Basel), 14(6):1420. https:\/\/doi.org\/10.3390\/cancers14061420","journal-title":"Cancers (Basel)"},{"issue":"4","key":"816_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al., 2019. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med, 381(4):317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"issue":"6","key":"816_CR42","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/cancers12061378","volume":"12","author":"A Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves A, Bertucci A, Bertucci F, 2020. PARP inhibitors in the treatment of early breast cancer: the step beyond? Cancers (Basel), 12(6): 1378. https:\/\/doi.org\/10.3390\/cancers12061378","journal-title":"Cancers (Basel)"},{"issue":"25","key":"816_CR43","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al., 2019. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"issue":"2","key":"816_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","volume":"18","author":"EL Gornstein","year":"2018","unstructured":"Gornstein EL, Sandefur S, Chung JH, et al., 2018. BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy. Clin Breast Cancer, 18(2):184\u2013188. https:\/\/doi.org\/10.1016\/j.clbc.2017.12.010","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"816_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdx505","volume":"29","author":"HS Han","year":"2018","unstructured":"Han HS, Di\u00e9ras V, Robson M, et al., 2018. Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study. Ann Oncol, 29(1):154\u2013161. https:\/\/doi.org\/10.1093\/annonc\/mdx505","journal-title":"Ann Oncol"},{"key":"816_CR46","doi-asserted-by":"publisher","first-page":"578095","DOI":"10.3389\/fonc.2020.578095","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Yu XP, Li SQ, et al., 2020. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Front Oncol, 10:578095. https:\/\/doi.org\/10.3389\/fonc.2020.578095","journal-title":"Front Oncol"},{"issue":"6","key":"816_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.tig.2019.03.008","volume":"35","author":"H Hanzlikova","year":"2019","unstructured":"Hanzlikova H, Caldecott KW, 2019. Perspectives on PARPs in S phase. Trends in Genetics, 35(6):412\u2013422. https:\/\/doi.org\/10.1016\/j.tig.2019.03.008","journal-title":"Trends in Genetics"},{"issue":"5","key":"816_CR48","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/nar\/gkw1246","volume":"45","author":"H Hanzlikova","year":"2017","unstructured":"Hanzlikova H, Gittens W, Krejcikova K, et al., 2017. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res, 45(5):2546\u20132557. https:\/\/doi.org\/10.1093\/nar\/gkw1246","journal-title":"Nucleic Acids Res"},{"key":"816_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fmolb.2020.00191","volume":"7","author":"D Harrision","year":"2020","unstructured":"Harrision D, Gravells P, Thompson R, et al., 2020. Poly(ADP-ribose) glycohydrolase (PARG) vs. poly(ADP-ribose) polymerase (PARP)\u2013function in genome maintenance and relevance of inhibitors for anti-cancer therapy. Front Mol Biosci, 7:191. https:\/\/doi.org\/10.3389\/fmolb.2020.00191","journal-title":"Front Mol Biosci"},{"issue":"17_suppl","key":"816_CR50","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"P Harter","year":"2023","unstructured":"Harter P, Trillsch F, Okamoto A, et al., 2023. Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (PTS) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol, 41(17_suppl):LBA5506. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA5506","journal-title":"J Clin Oncol"},{"key":"816_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes B, Murai J, Lee JM, 2018. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev, 71:1\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.003","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"816_CR52","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/ijms22063199","volume":"22","author":"J He","year":"2021","unstructured":"He J, Fortunati E, Liu DX, et al., 2021. Pleiotropic roles of ABC transporters in breast cancer. Int J Mol Sci, 22(6): 3199. https:\/\/doi.org\/10.3390\/ijms22063199","journal-title":"Int J Mol Sci"},{"key":"816_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00286","volume":"2","author":"AL Heeke","year":"2018","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, et al., 2018. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol, 2:1\u201313. https:\/\/doi.org\/10.1200\/PO.17.00286","journal-title":"JCO Precis Oncol"},{"issue":"4_suppl","key":"816_CR54","doi-asserted-by":"publisher","first-page":"OT2","DOI":"10.1158\/1538-7445.SABCS19-OT2-03-04","volume":"80","author":"AL Heeke","year":"2020","unstructured":"Heeke AL, Pishvaian M, Wang HK, et al., 2020. Abstract OT2-03-04: a trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: the TALAVE study. Cancer Res, 80(4_suppl): OT2\u201304. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-OT2-03-04","journal-title":"Cancer Res"},{"issue":"7","key":"816_CR55","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-19-2000","volume":"26","author":"F Higuchi","year":"2020","unstructured":"Higuchi F, Nagashima H, Ning JF, et al., 2020. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res, 26(7):1690\u20131699. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2000","journal-title":"Clin Cancer Res"},{"issue":"5","key":"816_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/gtc.12929","volume":"27","author":"K Hirota","year":"2022","unstructured":"Hirota K, Ooka M, Shimizu N, et al., 2022. XRCC1 counteracts poly(ADP ribose) polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Genes Cells, 27(5):331\u2013344. https:\/\/doi.org\/10.1111\/gtc.12929","journal-title":"Genes Cells"},{"key":"816_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctarc.2017.09.001","volume":"14","author":"M Hjortkj\u00e6r","year":"2018","unstructured":"Hjortkj\u00e6r M, Kanstrup H, Jakobsen A, et al., 2018. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treat Res Commun, 14:7\u201312. https:\/\/doi.org\/10.1016\/j.ctarc.2017.09.001","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"816_CR58","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE, et al., 2015. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res, 13(11): 1465\u20131477. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0191-T","journal-title":"Mol Cancer Res"},{"key":"816_CR59","doi-asserted-by":"publisher","first-page":"114094","DOI":"10.1016\/j.ejmech.2021.114094","volume":"230","author":"XY Hu","year":"2022","unstructured":"Hu XY, Zhang JF, Zhang Y, et al., 2022. Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: advances, challenges, and opportunities. Eur J Med Chem, 230:114094. https:\/\/doi.org\/10.1016\/j.ejmech.2021.114094","journal-title":"Eur J Med Chem"},{"issue":"6","key":"816_CR60","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/genes12060849","volume":"12","author":"S Jonuscheit","year":"2021","unstructured":"Jonuscheit S, Jost T, Gajdo\u0161ov\u00e1 F, et al., 2021. PARP inhibitors talazoparib and niraparib sensitize melanoma cells to ionizing radiation. Genes, 12(6):849. https:\/\/doi.org\/10.3390\/genes12060849","journal-title":"Genes"},{"issue":"16","key":"816_CR61","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1101\/gad.1955310","volume":"24","author":"Y Kee","year":"2010","unstructured":"Kee Y, D\u2019Andrea AD, 2010. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev, 24(16):1680\u20131694. https:\/\/doi.org\/10.1101\/gad.1955310","journal-title":"Genes Dev"},{"issue":"1","key":"816_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s43188-022-00146-0","volume":"39","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Lee K, Park J, et al., 2023. CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. Toxicol Res, 39(1):61\u201369. https:\/\/doi.org\/10.1007\/s43188-022-00146-0","journal-title":"Toxicol Res"},{"issue":"8","key":"816_CR63","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, et al., 2019. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncology, 5(8): 1141\u20131149. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1048","journal-title":"JAMA Oncology"},{"issue":"6","key":"816_CR64","doi-asserted-by":"publisher","first-page":"e100041","DOI":"10.1371\/journal.pone.0100041","volume":"9","author":"R Koppensteiner","year":"2014","unstructured":"Koppensteiner R, Samartzis EP, Noske A, et al., 2014. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE, 9(6):e100041. https:\/\/doi.org\/10.1371\/journal.pone.0100041","journal-title":"PLoS ONE"},{"key":"816_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2021.06.028","volume":"159","author":"DE Kozono","year":"2021","unstructured":"Kozono DE, Stinchcombe TE, Salama JK, et al., 2021. Veliparib in combination with carboplatin\/paclitaxel-based chemo-radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 159:56\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.028","journal-title":"Lung Cancer"},{"issue":"1","key":"816_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/GCO.0000000000000600","volume":"32","author":"K Kubalanza","year":"2020","unstructured":"Kubalanza K, Konecny GE, 2020. Mechanisms of PARP inhibitor resistance in ovarian cancer. Curr Opin Obstet Gynecol, 32(1):36\u201341. https:\/\/doi.org\/10.1097\/GCO.0000000000000600","journal-title":"Curr Opin Obstet Gynecol"},{"key":"816_CR67","series-title":"PhD Dissemination","volume-title":"A ligase IV\/XRCC4-dependent single strand break repair pathway for the maintenance of A\/T-rich regions during DNA replication in mammals","author":"N Kumari","year":"2023","unstructured":"Kumari N, 2023. A ligase IV\/XRCC4-dependent single strand break repair pathway for the maintenance of A\/T-rich regions during DNA replication in mammals. PhD Dissemination, Indian Institute of Science, Bangalore, Indian."},{"issue":"20","key":"816_CR68","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1158\/1078-0432.CCR-18-0401","volume":"24","author":"JH Laird","year":"2018","unstructured":"Laird JH, Lok BH, Ma J, et al., 2018. Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin Cancer Res, 24(20):5143\u20135152. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0401","journal-title":"Clin Cancer Res"},{"key":"816_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ctro.2019.12.005","volume":"21","author":"DS Lakomy","year":"2020","unstructured":"Lakomy DS, Urbauer DL, Westin SN, et al., 2020. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol, 21:56\u201361. https:\/\/doi.org\/10.1016\/j.ctro.2019.12.005","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"816_CR70","doi-asserted-by":"publisher","first-page":"168207","DOI":"10.1016\/j.jmb.2023.168207","volume":"436","author":"N Laspata","year":"2024","unstructured":"Laspata N, Muoio D, Fouquerel E, 2024. Multifaceted role of PARP1 in maintaining genome stability through its binding to alternative DNA structures. J Mol Biol, 436(1):168207. https:\/\/doi.org\/10.1016\/j.jmb.2023.168207","journal-title":"J Mol Biol"},{"issue":"9","key":"816_CR71","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/17512433.2018.1513321","volume":"11","author":"D Le","year":"2018","unstructured":"Le D, Gelmon KA, 2018. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Expert Rev Clin Pharmacol, 11(9):833\u2013839. https:\/\/doi.org\/10.1080\/17512433.2018.1513321","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"816_CR72","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/medicina56050212","volume":"56","author":"YC Lee","year":"2020","unstructured":"Lee YC, Lee YC, Li CY, et al., 2020. BRCA1 and BRCA2 gene mutations and lung cancer risk: a meta-analysis. Medicina, 56(5):212. https:\/\/doi.org\/10.3390\/medicina56050212","journal-title":"Medicina"},{"issue":"1","key":"816_CR73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"SY Li","year":"2022","unstructured":"Li SY, Wang LL, Wang YY, et al., 2022. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol, 15(1): 147\u2013147. https:\/\/doi.org\/10.1186\/s13045-022-01360-x","journal-title":"J Hematol Oncol"},{"issue":"5","key":"816_CR74","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ, 2018. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med, 215(5):1287\u20131299. https:\/\/doi.org\/10.1084\/jem.20180139","journal-title":"J Exp Med"},{"issue":"2","key":"816_CR75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, et al., 2019. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in highgrade ovarian carcinoma. Cancer Discov, 9(2):210\u2013219. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0715","journal-title":"Cancer Discov"},{"issue":"11","key":"816_CR76","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, et al., 2020. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the embraca trial. Ann Oncol, 31(11): 1526\u20131535. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2098","journal-title":"Ann Oncol"},{"issue":"3","key":"816_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/genes13030401","volume":"13","author":"Q Liu","year":"2022","unstructured":"Liu Q, Fang LM, Wu CJ, 2022. Alternative splicing and isoforms: from mechanisms to diseases. Genes (Basel), 13(3): 401. https:\/\/doi.org\/10.3390\/genes13030401","journal-title":"Genes (Basel)"},{"issue":"15_suppl","key":"816_CR78","doi-asserted-by":"publisher","first-page":"TPS1102","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1102","volume":"38","author":"P Lorusso","year":"2020","unstructured":"Lorusso P, Pilat MJP, Santa-Maria CA, et al., 2020. Trial in progress: a phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer. J Clin Oncol, 38(15_suppl): TPS1102. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS1102","journal-title":"J Clin Oncol"},{"key":"816_CR79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"YJ Lu","year":"2020","unstructured":"Lu YJ, Chan YT, Tan HY, et al., 2020. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer, 19:7. https:\/\/doi.org\/10.1186\/s12943-020-01197-3","journal-title":"Mol Cancer"},{"issue":"3","key":"816_CR80","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00432-019-03097-6","volume":"146","author":"J Luo","year":"2020","unstructured":"Luo J, Dai XC, Hu H, et al., 2020. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1\/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol, 146(3): 721\u2013737. https:\/\/doi.org\/10.1007\/s00432-019-03097-6","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"816_CR81","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F, 2018. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet, 19(2): 81\u201392. https:\/\/doi.org\/10.1038\/nrg.2017.80","journal-title":"Nat Rev Genet"},{"issue":"4","key":"816_CR82","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s43188-023-00199-9","volume":"39","author":"A Maharjan","year":"2023","unstructured":"Maharjan A, Gautam R, Acharya M, et al., 2023. Association of immunotoxicological indices with lung cancer biomarkers in poultry, grape, and rose farming workers. Toxicol Res, 39(4):739\u2013747. https:\/\/doi.org\/10.1007\/s43188-023-00199-9","journal-title":"Toxicol Res"},{"key":"816_CR83","doi-asserted-by":"publisher","first-page":"745981","DOI":"10.3389\/fonc.2021.745981","volume":"11","author":"E Matanes","year":"2021","unstructured":"Matanes E, L\u00f6pez-Ozuna VM, Octeau D, et al., 2021. Inhibition of poly ADP-ribose glycohydrolase sensitizes ovarian cancer cells to poly ADP-ribose polymerase inhibitors and platinum agents. Front Oncol, 11:745981. https:\/\/doi.org\/10.3389\/fonc.2021.745981","journal-title":"Front Oncol"},{"issue":"1","key":"816_CR84","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al., 2020. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol, 21(1):162\u2013174. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9","journal-title":"Lancet Oncol"},{"issue":"7713","key":"816_CR85","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al., 2018. High speed of fork progression induces DNA replication stress and genomic instability. Nature, 559(7713):279\u2013284. https:\/\/doi.org\/10.1038\/s41586-018-0261-5","journal-title":"Nature"},{"issue":"21","key":"816_CR86","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.3390\/cancers14215278","volume":"14","author":"C McCarthy-Leo","year":"2022","unstructured":"McCarthy-Leo C, Darwiche F, Tainsky MA, 2022. DNA repair mechanisms, protein interactions and therapeutic targeting of the MRN complex. Cancers (Basel), 14(21):5278. https:\/\/doi.org\/10.3390\/cancers14215278","journal-title":"Cancers (Basel)"},{"issue":"22","key":"816_CR87","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al., 2016. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med, 375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"issue":"9","key":"816_CR88","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.3390\/ijms21093122","volume":"21","author":"N Moor","year":"2020","unstructured":"Moor N, Vasil\u2019eva I, Lavrik O, 2020. Functional role of N-terminal extension of human AP endonuclease 1 in coordination of base excision DNA repair via protein\u2013protein interactions. Int J Mol Sci, 21(9):3122. https:\/\/doi.org\/10.3390\/ijms21093122","journal-title":"Int J Mol Sci"},{"issue":"5","key":"816_CR89","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, et al., 2019. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol, 20(5):636\u2013648. https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4","journal-title":"Lancet Oncol"},{"issue":"7","key":"816_CR90","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, et al., 2017. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov, 7(7):675\u2013693. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0226","journal-title":"Cancer Discov"},{"issue":"21","key":"816_CR91","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SYN, Das BB, et al., 2012. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res, 72(21): 5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753","journal-title":"Cancer Res"},{"issue":"10","key":"816_CR92","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum H, 2019. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol, 29(10):820\u2013834. https:\/\/doi.org\/10.1016\/j.tcb.2019.07.008","journal-title":"Trends Cell Biol"},{"issue":"8","key":"816_CR93","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh M, Alkhushaym N, Fallatah S, et al., 2019. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate, 79(8):880\u2013895. https:\/\/doi.org\/10.1002\/pros.23795","journal-title":"Prostate"},{"issue":"2","key":"816_CR94","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"Oza AM, Tinker AV, Oaknin A, et al., 2017. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2. Gynecol Oncol, 147(2):267\u2013275. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.022","journal-title":"Gynecol Oncol"},{"issue":"8","key":"816_CR95","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1073\/pnas.1013715108","volume":"108","author":"AG Patel","year":"2011","unstructured":"Patel AG, Sarkaria JN, Kaufmann SH, 2011. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA, 108(8):3406\u20133411. https:\/\/doi.org\/10.1073\/pnas.1013715108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"816_CR96","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, et al., 2021. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-OV21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 22(5):620\u2013631. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"816_CR97","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0014-5793(71)80524-0","volume":"19","author":"J Preiss","year":"1971","unstructured":"Preiss J, Schlaeger R, Hilz H, 1971. Specific inhibition of poly adpribose polymerase by thymidine and nicotinamide in HeLa cells. FEBS Lett, 19(3):244\u2013246. https:\/\/doi.org\/10.1016\/0014-5793(71)80524-0","journal-title":"FEBS Lett"},{"issue":"4","key":"816_CR98","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, et al., 2021. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open, 4(4):e214708. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.4708","journal-title":"JAMA Netw Open"},{"issue":"14","key":"816_CR99","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.3390\/cancers13143438","volume":"13","author":"L Raimundo","year":"2021","unstructured":"Raimundo L, Calheiros J, Saraiva L, 2021. Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target. Cancers (Basel), 13(14):3438. https:\/\/doi.org\/10.3390\/cancers13143438","journal-title":"Cancers (Basel)"},{"issue":"10","key":"816_CR100","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A, 2017. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol, 18(10):610\u2013621. https:\/\/doi.org\/10.1038\/nrm.2017.53","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"25","key":"816_CR101","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al., 2019. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med, 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"issue":"6","key":"816_CR102","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al., 2017. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med, 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"6","key":"816_CR103","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","volume":"14","author":"E Sachdev","year":"2019","unstructured":"Sachdev E, Tabatabai R, Roy V, et al., 2019. PARP inhibition in cancer: an update on clinical development. Targ Onco, 14(6):657\u2013679. https:\/\/doi.org\/10.1007\/s11523-019-00680-2","journal-title":"Targ Onco"},{"key":"816_CR104","series-title":"PhD Thesis","volume-title":"Role of PARP1 and NAD1 bioavailability in base excision and single-strand break repair","author":"KM Saville","year":"2022","unstructured":"Saville KM, 2022. Role of PARP1 and NAD1 bioavailability in base excision and single-strand break repair. PhD Thesis, University of South Alabama, United States. https:\/\/jagworks.southalabama.edu\/theses_diss\/98"},{"issue":"2","key":"816_CR105","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"JF Shen","year":"2019","unstructured":"Shen JF, Zhao W, Ju ZL, et al., 2019. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res, 79(2):311\u2013319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003","journal-title":"Cancer Res"},{"key":"816_CR106","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/s12885-018-4592-2","volume":"18","author":"Y Sheng","year":"2018","unstructured":"Sheng Y, Xu ME, Li CY, et al., 2018. Nm23-H1 is involved in the repair of ionizing radiation-induced DNA doublestrand breaks in the A549 lung cancer cell line. BMC Cancer, 18:710. https:\/\/doi.org\/10.1186\/s12885-018-4592-2","journal-title":"BMC Cancer"},{"issue":"9","key":"816_CR107","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/genes12091370","volume":"12","author":"A Shibata","year":"2021","unstructured":"Shibata A, Jeggo PA, 2021. ATM\u2019s role in the repair of DNA double-strand breaks. Genes (Basel), 12(9): 1370. https:\/\/doi.org\/10.3390\/genes12091370","journal-title":"Genes (Basel)"},{"issue":"10147","key":"816_CR108","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE, 2018. Acute myeloid leukaemia. Lancet, 392(10147):593\u2013606. https:\/\/doi.org\/10.1016\/S0140-6736(18)31041-9","journal-title":"Lancet"},{"issue":"1","key":"816_CR109","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/PPO.0000000000000568","volume":"28","author":"NJ Short","year":"2022","unstructured":"Short NJ, Dombret H, Ad\u00e8s L, et al., 2022. The evolution of research and therapy with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: new directions for old drugs. Cancer J, 28(1):29\u201336. https:\/\/doi.org\/10.1097\/PPO.0000000000000568","journal-title":"Cancer J"},{"key":"816_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00316","volume":"2","author":"RT Shroff","year":"2018","unstructured":"Shroff RT, Hendifar A, McWilliams RR, et al., 2018. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol, 2:1\u201315. https:\/\/doi.org\/10.1200\/PO.17.00316","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"816_CR111","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/biomedicines9111512","volume":"9","author":"DD Singh","year":"2021","unstructured":"Singh DD, Parveen A, Yadav DK, 2021. Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance. Biomedicines, 9(11):1512. https:\/\/doi.org\/10.3390\/biomedicines9111512","journal-title":"Biomedicines"},{"issue":"7","key":"816_CR112","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/cancers9070081","volume":"9","author":"BJ Sishc","year":"2017","unstructured":"Sishc BJ, Davis AJ, 2017. The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers (Basel), 9(7):81. https:\/\/doi.org\/10.3390\/cancers9070081","journal-title":"Cancers (Basel)"},{"issue":"7","key":"816_CR113","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/1541-7786.MCR-18-0106","volume":"16","author":"ST Sizemore","year":"2018","unstructured":"Sizemore ST, Mohammad R, Sizemore GM, et al., 2018. Synthetic lethality of PARP inhibition and ionizing radiation is p53-dependent. Mol Cancer Res, 16(7): 1092\u20131102. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-18-0106","journal-title":"Mol Cancer Res"},{"issue":"15","key":"816_CR114","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","volume":"23","author":"G Somlo","year":"2017","unstructured":"Somlo G, Frankel PH, Arun BK, et al., 2017. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res, 23(15):4066\u20134076. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2714","journal-title":"Clin Cancer Res"},{"issue":"3","key":"816_CR115","doi-asserted-by":"publisher","first-page":"e1241854","DOI":"10.1080\/23723556.2016.1241854","volume":"5","author":"V Stavropoulou","year":"2018","unstructured":"Stavropoulou V, Peters AHFM, Schwaller J, 2018. Aggressive leukemia driven by MLL-AF9. Mol Cell Oncol, 5(3): e1241854. https:\/\/doi.org\/10.1080\/23723556.2016.1241854","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"816_CR116","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"816_CR117","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/ijms22062840","volume":"22","author":"M Svetec Mikleni\u0107","year":"2021","unstructured":"Svetec Mikleni\u0107 M, Svetec IK, 2021. Palindromes in DNA\u2014 a risk for genome stability and implications in cancer. Int J Mol Sci, 22(6):2840. https:\/\/doi.org\/10.3390\/ijms22062840","journal-title":"Int J Mol Sci"},{"issue":"2","key":"816_CR118","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2021.12.003","volume":"164","author":"EM Swisher","year":"2022","unstructured":"Swisher EM, Aghajanian C, O\u2019Malley DM, et al., 2022. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the phase 3 VELIA\/GOG-3005 study. Gynecol Oncol, 164(2):245\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.003","journal-title":"Gynecol Oncol"},{"key":"816_CR119","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","volume":"40","author":"R Tuli","year":"2019","unstructured":"Tuli R, Shiao SL, Nissen N, et al., 2019. A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine, 40:375\u2013381. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.060","journal-title":"EBioMedicine"},{"issue":"8","key":"816_CR120","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.3390\/ijms22084203","volume":"22","author":"G Valabrega","year":"2021","unstructured":"Valabrega G, Scotto G, Tuninetti V, et al., 2021. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci, 22(8):4203. https:\/\/doi.org\/10.3390\/ijms22084203","journal-title":"Int J Mol Sci"},{"issue":"6","key":"816_CR121","doi-asserted-by":"publisher","first-page":"180037","DOI":"10.1098\/rsob.180037","volume":"8","author":"J van den Bulk","year":"2018","unstructured":"van den Bulk J, Verdegaal EME, de Miranda NFCC, 2018. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol, 8(6):180037. https:\/\/doi.org\/10.1098\/rsob.180037","journal-title":"Open Biol"},{"issue":"8","key":"816_CR122","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, et al., 2019. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol, 5(8): 1132\u20131140. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029","journal-title":"JAMA Oncol"},{"key":"816_CR123","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.critrevonc.2018.05.008","volume":"127","author":"S Vos","year":"2018","unstructured":"Vos S, van Diest PJ, Moelans CB, 2018. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: mutually exclusive, or not? Crit Rev Oncol Hematol, 127:29\u201341. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.05.008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"816_CR124","doi-asserted-by":"publisher","first-page":"e149526","DOI":"10.1172\/JCI149526","volume":"132","author":"JJ Wang","year":"2022","unstructured":"Wang JJ, Zhu X, Dang L, et al., 2022. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4; 14) translocation. J Clin Invest, 132(4):e149526. https:\/\/doi.org\/10.1172\/JCI149526","journal-title":"J Clin Invest"},{"issue":"3","key":"816_CR125","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Yang CY, Xie CY, et al., 2019. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci, 110(3):1064\u20131075. https:\/\/doi.org\/10.1111\/cas.13947","journal-title":"Cancer Sci"},{"issue":"21","key":"816_CR126","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1093\/nar\/gkl840","volume":"34","author":"ML Wang","year":"2006","unstructured":"Wang ML, Wu WZ, Wu WQ, et al., 2006. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res, 34(21):6170\u20136182. https:\/\/doi.org\/10.1093\/nar\/gkl840","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"816_CR127","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/biom11050722","volume":"11","author":"MY Xia","year":"2021","unstructured":"Xia MY, Guo ZG, Hu ZG, 2021. The role of PARP inhibitors in the treatment of prostate cancer: recent advances in clinical trials. Biomolecules, 11(5):722. https:\/\/doi.org\/10.3390\/biom11050722","journal-title":"Biomolecules"},{"issue":"25","key":"816_CR128","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM, 2017. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med, 377(25):2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"issue":"22","key":"816_CR129","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/cmdc.202000391","volume":"15","author":"NA Yusoh","year":"2020","unstructured":"Yusoh NA, Ahmad H, Gill MR, 2020. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem, 15(22):2121\u20132135. https:\/\/doi.org\/10.1002\/cmdc.202000391","journal-title":"ChemMedChem"},{"issue":"1","key":"816_CR130","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"JH Zhang","year":"2012","unstructured":"Zhang JH, Stevens MFG, Bradshaw TD, 2012. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol, 5(1):102\u2013114. https:\/\/doi.org\/10.2174\/1874467211205010102","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"816_CR131","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/C8CC07813K","volume":"55","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Lan TL, Su S, et al., 2019. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun, 55(3):369\u2013372. https:\/\/doi.org\/10.1039\/C8CC07813K","journal-title":"Chem Commun"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2400146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2400146\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2400146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:02:48Z","timestamp":1765440168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2400146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":131,"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2400146","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, and Wanxia PU declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}